Table 1.
Screened drugs with selective sensitivity targeting glycolysis-associated signature.
| GDSC name | P-Value | Targets | Target pathway |
|---|---|---|---|
| CCT007093 | <0.0001 | PPM1D | Cell cycle |
| Tretinoin | <0.0001 | Retinoic acid | Other |
| Navitoclax | <0.0001 | BCL2, BCL-XL, BCL-W | Apoptosis regulation |
| Imatinib | <0.0001 | ABL, KIT, PDGFR | Kinases |
| VX702 | <0.0001 | p38 | JNK and p38 signaling |
| Pictilisib | <0.0001 | PI3K | PI3K/MTOR signaling |
| Rucaparib | <0.0001 | PARP1, PARP2 | Genome integrity |
| AZD6482 | <0.0001 | PI3Kbeta | PI3K/MTOR signaling |
| Crizotinib | <0.0001 | MET, ALK, ROS1 | RTK signaling |
| Vorinostat | <0.0001 | HDAC inhibitor Class I, IIa, IIb, IV | Chromatin histone acetylation |
| MK2206 | <0.0001 | AKT1, AKT2 | PI3K/MTOR signaling |
| AZD8055 | <0.0001 | MTORC1, MTORC2 | PI3K/MTOR signaling |
| Motesanib | <0.0001 | VEGFR, RET, KIT, PDGFR | RTK signaling |
| Serdemetan | <0.0001 | MDM2 | p53 pathway |
| Linsitinib | <0.0001 | IGF1R | IGF1R signaling |
| Axitinib | <0.0001 | PDGFR, KIT, VEGFR | RTK signaling |
| IPA-3 | 0.0002 | PAK1 | Cytoskeleton |
| LFM-A13 | 0.0003 | BTK | Kinases |
| BAY-61-3606 | 0.0005 | SYK | Kinases |
| PD173074 | 0.0006 | FGFR1, FGFR3 | RTK signaling |
| PAC-1 | 0.0006 | Procaspase-3, Procaspase-7 | Apoptosis regulation |
| TW37 | 0.0025 | BCL2, BCL-XL, MCL1 | Apoptosis regulation |
| Doramapimod | 0.0116 | p38, JNK2 | JNK and p38 signaling |
| Elesclomol | 0.012 | HSP90 | Protein stability and degradation |
| DMOG | 0.0248 | HIF-PH | Metabolism |
| PHA-665752 | 0.0311 | MET | RTK signaling |